Study on Gemcitabine, Nab-paclitaxel, and TheraBionic P1 Device for Treating Metastatic Pancreatic Cancer

Inclusion Criteria

• Have a confirmed diagnosis of advanced pancreatic cancer.
• Have at least one tumor that can be measured using scans like CT, MRI, or PET.
• Women who can become pregnant must have a negative pregnancy test before starting treatment.
• If sexually active, both men and women must agree to use two forms of birth control during treatment and for six months after.
• Be 18 years or older.
• Patients 80 years and older need a thorough health evaluation before joining the study.
• Be in good overall health with a performance status score of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Meet specific blood test requirements for neutrophil count, platelets, liver function, and kidney function.
• Be able to understand and sign a consent form agreeing to participate in the study.

Exclusion Criteria

• Have received gemcitabine or nab-paclitaxel chemotherapy within the last six months.
• Are taking part in another clinical trial.
• Have cancer that has spread to the brain.
• Have allergies to similar drugs as those used in the study.
• Have had another cancer in the last three years, except for certain skin or prostate cancers.
• Are taking certain medications like calcium channel blockers unless they can be stopped before joining the study.
• Have an active infection that requires treatment.
• Have serious health conditions like heart failure or unstable angina.
• Have lung diseases like interstitial lung disease or pulmonary fibrosis.
• Are pregnant or breastfeeding.
• Have a tumor that can be surgically removed or is locally advanced.
• Have had major surgery within four weeks before starting the study.
• Cannot follow the study procedures or expect to need a break from treatment for 14 or more days.
• Are enrolled in another clinical trial.